<ul>
<li>启动目标为 160 亿美元的 SGLT-2 抑制剂市场，服务于美国 3300 万名 2 型糖尿病患者，其中许多人没有保险或保险不足，且自付费用超过 Brenzavvy 的现金价格</li>
<li>专有的 EinsteinRx™人工智能药房平台使 Wellgistics 药房网络中的 6500 多家药房能够教育患者和提供者，了解 Brenzavvy 与 Jardiance®及其他 SGLT-2 抑制剂的优势</li>
<li>降低患者的自付费用，并为药剂师提供患者教育的收入机会，旨在支持 Brenzavvy 的更广泛市场准入，并提升整体护理体验</li>
<li>启动建立了一种新模型，针对下一代改良药物，提供与市场领导者相比的患者特定产品优势</li>
</ul>
<p><strong>Wellgistics Health, Inc.（&#34;Wellgistics&#34;）（NASDAQ:WGRX）</strong>，一家健康信息技术领导者，将专有的药房分发优化人工智能平台 <strong>EinsteinRx</strong> _<strong>™</strong>_整合到其专利的区块链智能合约平台 <strong>PharmacyChain™</strong> 中，今天宣布已开始在其 6500 家独立药房网络（&#34;Wellgistics 药房网络&#34;）中商业推出糖尿病处方药 Brenzavvy®，该网络主要针对农村社区的患者，这些地区通常糖尿病发病率较高。此次推出的目标是 3300 万名被诊断为 2 型糖尿病的美国人 [1]，他们的 SGLT-2 药物自付费用超过 Brenzavvy 的现金价格。</p>
<p>Jardiance®和其他 SGLT-2 抑制剂药物在 2024 年的销售额达到 168 亿美元，预计到 2033 年将增长至 289 亿美元。根据 Grandview Research 的数据，美国占该市场的 40.8%。对 2022-2023 年 28 个美国健康系统的数据进行的大规模分析显示，糖尿病患者中推荐使用 SGLT-2 抑制剂的处方仅为 11.9%[3]，导致绝大多数患者的护理不理想。随着公司的专有 <strong>EinsteinRx</strong> 人工智能药房平台在 Wellgistics 药房网络的销售点系统中推出，Wellgistics 将提醒药剂师关注可能符合 SGLT-2 抑制剂 1A 类推荐的患者，以及在大多数没有此类 1A 类推荐的情况下，使用 Brenzavvy 与其他 SGLT-2 抑制剂相比的潜在患者获益。一旦被提醒，药剂师将能够迅速教育提供者，说明 Brenzavvy 与其他 SGLT-2 抑制剂在没有心血管疾病或慢性肾病（CKD）患者中的优势。Brenzavvy 与 Jardiance 及其他 SGLT-2 抑制剂的自付费用相比，具有竞争力的价格，为药剂师主导的教育提供了有力的理由，以帮助优化处方决策并改善患者的获取。</p>
<p>&#34;通过迅速帮助提供者优化患者的治疗选择，而不延迟药物发放时间，药剂师在帮助患者获得更好结果方面处于独特的位置，而无需增加自付费用，&#34;Wellgistics Health 的总裁兼临时首席执行官 Prashant Patel，RPh 表示。&#34;药剂师是关于处方药如何影响患者健康的最可信的信息来源之一，尤其是在农村社区。<strong>EinsteinRx</strong> 正在赋能这些受信任的医疗专业人员，提供他们所需的先进技术，以便在正确的时间将正确的药物提供给正确的患者。通过我们的 Wellgistics 药房网络推出 Brenzavvy，我们可以为产品和服务提供报酬机会，后者帮助药剂师通过教育提供者了解 Brenzavvy 的患者特定优势来提高投资回报率。我们相信，这种药剂师主导的提供者教育模式将为其他具有类似产品优势的后续药物快速建立市场份额提供蓝图。&#34;</p>
<p><strong>关于 Wellgistics Health, Inc.</strong></p>
<p>Wellgistics Health（NASDAQ: WGRX）是一家健康信息技术领导者，将专有的药房分发优化人工智能平台 EinsteinRx™整合到其专利的区块链智能合约平台 PharmacyChain™中，以优化处方药的发放过程。其集成平台连接 6500 多家药房（&#34;Wellgistics 药房网络&#34;）和 200 多家制造商，提供批发分销、数字处方路由、直接送药到患者以及 AI 驱动的中心服务，如资格审核、依从性、入职、事先授权和现金支付履行等，以优化患者的获取。Wellgistics 提供端到端解决方案，旨在恢复美国独立药房处方药市场的获取、透明度和信任。</p>
<p>欲了解更多信息，请访问 www.wellgisticshealth.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据联邦证券法的定义的前瞻性声明，包括但不限于关于各方计划谈判最终协议、潜在实施、采用、表现、收入分享及其他预期利益的声明。这些声明面临风险和不确定性，可能导致实际结果与预期结果有重大差异，包括在 DataVault AI, Inc.和 Wellgistics Health, Inc.向 SEC 提交的文件中所述的风险。前瞻性声明仅在本日期有效，且两家公司均不承担更新这些声明的义务，除非法律要求。其他因素在 Wellgistics Health 向 SEC 提交的文件中进行了讨论，相关文件可在 www.sec.gov 获取。</p>
<p>本新闻稿不构成在任何司法管辖区出售或招揽购买任何证券的要约，并且在任何此类要约、招揽或销售违法的司法管辖区内将不进行证券的销售。</p>
<p><strong>Wellgistics 媒体与投资者联系</strong></p>
<p>媒体：</p>
<p>media@wellgisticshealth.com</p>
<p>投资者关系：</p>
<p>IR@wellgisticshealth.com</p>
<p><strong>Wellgistics 投资者关系联系人</strong></p>
<p>Skyline Corporate Communications Group, LLC</p>
<p>Scott Powell, 总裁</p>
<p>1177 Avenue of the Americas, 5th Floor</p>
<p>New York, NY 10036</p>
<p>办公室： (646) 893-5835</p>
<p>电子邮件： info@skylineccg.com</p>
<p>[1] https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes</p>
<p>[2] https://www.grandviewresearch.com/industry-analysis/sglt2-inhibitors-market-report</p>
<p>[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC11789666.</p>
<p><strong>来源：</strong> Wellgistics Health, Inc.</p>
<p>查看原始新闻稿请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNTM2NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNTM2NQ"/></p>

WGRX

<p>Wellgistics Health 推出了 Brenzavvy，这是一种针对 160 亿美元 SGLT-2 抑制剂市场的糖尿病药物。此次推出旨在降低美国 3300 万名 2 型糖尿病患者的自付费用，利用 EinsteinRx 人工智能平台来教育药剂师和医疗提供者。Brenzavvy 提供具有竞争力的定价和针对患者的优势，增强市场准入和护理体验。该倡议支持药剂师主导的教育，以优化治疗选择，特别是在农村社区，并建立了一种重新配方药物获得市场份额的模式</p>

<ul>
<li>Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price</li>
<li>Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors</li>
<li>Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience</li>
<li>Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders</li>
</ul>
<div class="lb-trans"><ul>
<li>启动目标为 160 亿美元的 SGLT-2 抑制剂市场，服务于美国 3300 万名 2 型糖尿病患者，其中许多人没有保险或保险不足，且自付费用超过 Brenzavvy 的现金价格</li>
<li>专有的 EinsteinRx™人工智能药房平台使 Wellgistics 药房网络中的 6500 多家药房能够教育患者和提供者，了解 Brenzavvy 与 Jardiance®及其他 SGLT-2 抑制剂的优势</li>
<li>降低患者的自付费用，并为药剂师提供患者教育的收入机会，旨在支持 Brenzavvy 的更广泛市场准入，并提升整体护理体验</li>
<li>启动建立了一种新模型，针对下一代改良药物，提供与市场领导者相比的患者特定产品优势</li>
</ul>
</div><p><strong>Wellgistics Health, Inc. (&#34;Wellgistics&#34;) (NASDAQ:WGRX)</strong>, a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform <strong>EinsteinRx</strong> <em><strong>™</strong></em> into its patented blockchain-enabled smart contracts platform <strong>PharmacyChain™</strong>, today announced that it has begun the commercial launch of diabetes prescription drug Brenzavvy® to its network of 6,500 independent pharmacies (the &#34;Wellgistics Pharmacy Network&#34;) that primarily target patients in rural communities where there is often an increased incidence of diabetes. The launch is targeting the 33 million Americans who have been diagnosed with type II diabetes[1] and whose out-of-pocket costs for SGLT-2 drugs exceed the Brenzavvy cash price.</p>
<div class="lb-trans"><p><strong>Wellgistics Health, Inc.（&#34;Wellgistics&#34;）（NASDAQ:WGRX）</strong>，一家健康信息技术领导者，将专有的药房分发优化人工智能平台 <strong>EinsteinRx</strong> _<strong>™</strong>_整合到其专利的区块链智能合约平台 <strong>PharmacyChain™</strong> 中，今天宣布已开始在其 6500 家独立药房网络（&#34;Wellgistics 药房网络&#34;）中商业推出糖尿病处方药 Brenzavvy®，该网络主要针对农村社区的患者，这些地区通常糖尿病发病率较高。此次推出的目标是 3300 万名被诊断为 2 型糖尿病的美国人 [1]，他们的 SGLT-2 药物自付费用超过 Brenzavvy 的现金价格。</p>
</div><p>Jardiance® and other SGLT-2 inhibitor drugs reached sales of $16.8 billion in 2024, with projected growth projected to reach $28.9 billion by 2033. The United States represents 40.8% of that market according to Grandview Research[2]. A large scale analysis of data from 28 US health systems in 2022-2023 showed that guideline-recommended prescription of SGLT-2 inhibitors in diabetics with a class 1A recommendation is only 11.9%[3], leading to suboptimal care for the vast majority of such patients. As the Company's proprietary <strong>EinsteinRx</strong> artificial intelligence pharmacy platform is being rolled out into the Wellgistics Pharmacy Network's point-of-sales systems, Wellgistics will alert pharmacists to patients with a likely class 1A recommendation for a SGLT-2 inhibitor, as well as the likely patient benefit from dispensing Brenzavvy vs. other SGLT-2 inhibitors in the majority of cases where such a class 1A recommendation does not exist. Once alerted, pharmacists will be able to work to rapidly educate the provider on the benefits of Brenzavvy vs. other SGLT-2 inhibitors in patients without cardiovascular disease or chronic kidney disease (CKD). Brenzavvy's competitive price point when compared with the out-of-pocket costs of Jardiance &amp; other SGLT-2 inhibitors, provides a compelling rationale for pharmacist-driven education of providers to help optimize prescribing decisions and help improve patient access.</p>
<div class="lb-trans"><p>Jardiance®和其他 SGLT-2 抑制剂药物在 2024 年的销售额达到 168 亿美元，预计到 2033 年将增长至 289 亿美元。根据 Grandview Research 的数据，美国占该市场的 40.8%。对 2022-2023 年 28 个美国健康系统的数据进行的大规模分析显示，糖尿病患者中推荐使用 SGLT-2 抑制剂的处方仅为 11.9%[3]，导致绝大多数患者的护理不理想。随着公司的专有 <strong>EinsteinRx</strong> 人工智能药房平台在 Wellgistics 药房网络的销售点系统中推出，Wellgistics 将提醒药剂师关注可能符合 SGLT-2 抑制剂 1A 类推荐的患者，以及在大多数没有此类 1A 类推荐的情况下，使用 Brenzavvy 与其他 SGLT-2 抑制剂相比的潜在患者获益。一旦被提醒，药剂师将能够迅速教育提供者，说明 Brenzavvy 与其他 SGLT-2 抑制剂在没有心血管疾病或慢性肾病（CKD）患者中的优势。Brenzavvy 与 Jardiance 及其他 SGLT-2 抑制剂的自付费用相比，具有竞争力的价格，为药剂师主导的教育提供了有力的理由，以帮助优化处方决策并改善患者的获取。</p>
</div><p>&#34;By rapidly helping providers optimize therapy selection for patients without delaying dispensing timelines, pharmacists are uniquely positioned to help drive better outcomes for their patients without increasing out-of-pocket costs,&#34; said Prashant Patel, RPh, President &amp; Interim-CEO of Wellgistics Health. &#34;Pharmacists are one of the most trusted sources of information about how prescription drugs will impact the health of patients, especially in rural communities. <strong>EinsteinRx</strong> is empowering these trusted healthcare professionals with the advanced technology they need to get the right drug to the right patient at the right time. With the launch of Brenzavvy through our Wellgistics Pharmacy Network, we can provide remuneration opportunities for both products and services, with the latter helping pharmacists improve their ROI by educating providers on the patient-specific advantages of Brenzavvy. We believe that this pharmacist-led provider education model will enable the blueprint for other later-generation drugs with similar product profile advantages to rapidly establish market share.&#34;</p>
<div class="lb-trans"><p>&#34;通过迅速帮助提供者优化患者的治疗选择，而不延迟药物发放时间，药剂师在帮助患者获得更好结果方面处于独特的位置，而无需增加自付费用，&#34;Wellgistics Health 的总裁兼临时首席执行官 Prashant Patel，RPh 表示。&#34;药剂师是关于处方药如何影响患者健康的最可信的信息来源之一，尤其是在农村社区。<strong>EinsteinRx</strong> 正在赋能这些受信任的医疗专业人员，提供他们所需的先进技术，以便在正确的时间将正确的药物提供给正确的患者。通过我们的 Wellgistics 药房网络推出 Brenzavvy，我们可以为产品和服务提供报酬机会，后者帮助药剂师通过教育提供者了解 Brenzavvy 的患者特定优势来提高投资回报率。我们相信，这种药剂师主导的提供者教育模式将为其他具有类似产品优势的后续药物快速建立市场份额提供蓝图。&#34;</p>
</div><p><strong>About Wellgistics Health, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Wellgistics Health, Inc.</strong></p>
</div><p>Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the &#34;Wellgistics Pharmacy Network&#34;) and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.</p>
<div class="lb-trans"><p>Wellgistics Health（NASDAQ: WGRX）是一家健康信息技术领导者，将专有的药房分发优化人工智能平台 EinsteinRx™整合到其专利的区块链智能合约平台 PharmacyChain™中，以优化处方药的发放过程。其集成平台连接 6500 多家药房（&#34;Wellgistics 药房网络&#34;）和 200 多家制造商，提供批发分销、数字处方路由、直接送药到患者以及 AI 驱动的中心服务，如资格审核、依从性、入职、事先授权和现金支付履行等，以优化患者的获取。Wellgistics 提供端到端解决方案，旨在恢复美国独立药房处方药市场的获取、透明度和信任。</p>
</div><p>For more information, visit www.wellgisticshealth.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.wellgisticshealth.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward‑looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.'s and Wellgistics Health, Inc.'s filings with the SEC. Forward‑looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.</p>
<div class="lb-trans"><p>本新闻稿包含根据联邦证券法的定义的前瞻性声明，包括但不限于关于各方计划谈判最终协议、潜在实施、采用、表现、收入分享及其他预期利益的声明。这些声明面临风险和不确定性，可能导致实际结果与预期结果有重大差异，包括在 DataVault AI, Inc.和 Wellgistics Health, Inc.向 SEC 提交的文件中所述的风险。前瞻性声明仅在本日期有效，且两家公司均不承担更新这些声明的义务，除非法律要求。其他因素在 Wellgistics Health 向 SEC 提交的文件中进行了讨论，相关文件可在 www.sec.gov 获取。</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.</p>
<div class="lb-trans"><p>本新闻稿不构成在任何司法管辖区出售或招揽购买任何证券的要约，并且在任何此类要约、招揽或销售违法的司法管辖区内将不进行证券的销售。</p>
</div><p><strong>Wellgistics Media &amp; Investor Contact</strong></p>
<div class="lb-trans"><p><strong>Wellgistics 媒体与投资者联系</strong></p>
</div><p>Media:</p>
<div class="lb-trans"><p>媒体：</p>
</div><p>media@wellgisticshealth.com</p>
<div class="lb-trans"><p>media@wellgisticshealth.com</p>
</div><p>Investor Relations:</p>
<div class="lb-trans"><p>投资者关系：</p>
</div><p>IR@wellgisticshealth.com</p>
<div class="lb-trans"><p>IR@wellgisticshealth.com</p>
</div><p><strong>Wellgistics Investor Relations Contact</strong></p>
<div class="lb-trans"><p><strong>Wellgistics 投资者关系联系人</strong></p>
</div><p>Skyline Corporate Communications Group, LLC</p>
<div class="lb-trans"><p>Skyline Corporate Communications Group, LLC</p>
</div><p>Scott Powell, President</p>
<div class="lb-trans"><p>Scott Powell, 总裁</p>
</div><p>1177 Avenue of the Americas, 5th Floor</p>
<div class="lb-trans"><p>1177 Avenue of the Americas, 5th Floor</p>
</div><p>New York, NY 10036</p>
<div class="lb-trans"><p>New York, NY 10036</p>
</div><p>Office: (646) 893-5835</p>
<div class="lb-trans"><p>办公室： (646) 893-5835</p>
</div><p>Email: info@skylineccg.com</p>
<div class="lb-trans"><p>电子邮件： info@skylineccg.com</p>
</div><p>[1] https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes</p>
<div class="lb-trans"><p>[1] https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes</p>
</div><p>[2] https://www.grandviewresearch.com/industry-analysis/sglt2-inhibitors-market-report</p>
<div class="lb-trans"><p>[2] https://www.grandviewresearch.com/industry-analysis/sglt2-inhibitors-market-report</p>
</div><p>[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC11789666.</p>
<div class="lb-trans"><p>[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC11789666.</p>
</div><p><strong>SOURCE:</strong> Wellgistics Health, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Wellgistics Health, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNTM2NQ" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1115365"/></p>

Wellgistics Health 宣布将糖尿病药物 Brenzavvy(R) 推向 Wellgistics 药房网络 | WGRX 股票新闻